Document is current
Any future updates will be listed below
-
Authors
Alexdottir, Marta S.
Bourgonje, Arno R.
Tsapanou-Katranara, Thomai
Pehrsson, Martin
Godskesen, Line E.
Loveikyte, Roberta
Visschedijk, Marijn C.
Festen, Eleonora A. M.
Weersma, Rinse K.
Bay-Jensen, Anne-Christine
Karsdal, Morten A.
Krag, Aleksander
Kjeldsen, Jens
Dijkstra, Gerard
Mortensen, Joachim H.
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (452022317)
EU Horizon Health consortium (101136582)
Innovation Health Initiative Joint Undertaking (101194780)
EU Horizon Europe Program (101095470)
- License Information
-
More Information
Article History
Received: 16 January 2026
Accepted: 13 April 2026
First Online: 25 April 2026
Declarations
:
: MA, ACBJ, MK and JHM are employees of Nordic Bioscience. ACBJ, MK, and JHM are shareholders in Nordic Bioscience. GD received an unrestricted research grant from Takeda and speaker fees from Pfizer and Janssen Pharmaceuticals, outside the submitted work. GD and ARB have received a research grant from Janssen Pharmaceuticals, outside the submitted work. ARB received speaker’s fees from AbbVie and Ferring, outside the submitted work. All other authors have no competing interest to declare.
